<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01154361</url>
  </required_header>
  <id_info>
    <org_study_id>AMACE</org_study_id>
    <nct_id>NCT01154361</nct_id>
  </id_info>
  <brief_title>AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study</brief_title>
  <official_title>A Multicenter Study, Randomized, Double-blind With 2 Groups as Prove of Concept for the Treatment of ACEI Induced Angioedema With Subcutaneous Icatibant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <brief_summary>
    <textblock>
      This is a multicenter study recruiting patients with angioedema induced by ACEI.&#xD;
&#xD;
      Open-label treatment with subcutaneous Icatibant compared to a historic group of 47 patients&#xD;
      with ACE inhibitor induced angioedema which the investigators have been previously treated in&#xD;
      the investigators centers with current &quot;standard&quot; therapy (250 mg methylprednisolon and 2 mg&#xD;
      clemastine).&#xD;
&#xD;
      In cases with fast progression of edema after application the study-drug, a second&#xD;
      application with icatibant could be necessary. Rescue medication and intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sudden occurrence of subcutaneous or submucosal non-itchy swelling, so-called angioedema, is&#xD;
      a well known side effect of angiotensin-converting enzyme inhibitors (ACEi), which may become&#xD;
      life-threatening if the upper airway is involved. To be note, ACEi induced angioedema were&#xD;
      always located in the head and neck region.&#xD;
&#xD;
      The pathophysiology of ACE inhibitor (ACEi) induced angioedema most likely resembles that of&#xD;
      hereditary angioedema (HAE), i.e. it is mainly mediated by bradykinin induced activation of&#xD;
      vascular bradykinin B2 receptors (BKR-2). In contrast to an increased bradykinin generation&#xD;
      in HAE, treatment with ACEi decreases the bradykinin degradation in plasma and increases the&#xD;
      biological activity of bradykinin.&#xD;
&#xD;
      The current pharmacotherapy of ACEi induced angioedema is not satisfactory. Antihistamines&#xD;
      and corticosteroids may be effective in the treatment of urticaria with cutaneous edema and&#xD;
      itchy, but are theoretically ineffective and hence superfluous in bradykinin induced&#xD;
      angioedema. However, glucocorticoids still belong to the standard treatment of angioedema.&#xD;
&#xD;
      We hypothesized that the BKR-2 antagonist icatibant might be an effective therapy for&#xD;
      ACEi-induced angioedema.&#xD;
&#xD;
      Patients with ACEi induced angioedema, located in the upper aero-digestive tract will be&#xD;
      randomized and treated either with icatibant and plazebo or cortisone with clemastin and&#xD;
      plazebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to complete resolution of angioedema</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Angioedema</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icatibant (subcutaneous) and plazebo (intravenous)</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cortisone + Clemastin (intravenous) and plazebo (subcutaneous)</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 &lt;85 years&#xD;
&#xD;
          -  Patient is currently treated with an ACEI&#xD;
&#xD;
          -  Patient must have acute angioedema attack caused by an ACEI&#xD;
&#xD;
          -  Treatment should be administrated within 10 hrs after onset by an ACEI&#xD;
&#xD;
          -  Patient with angioedema of head and /or neck (face, lips, cheeks, tongue, soft&#xD;
             palate/uvula, pharynx and larynx)&#xD;
&#xD;
          -  At least one moderate to severe severe angioedema symptom as assessed by the&#xD;
             investigator, requiring a medical intervention&#xD;
&#xD;
          -  Signed written Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of angioedema that was not caused by ACEI: e.g. hereditary angioedema&#xD;
             (C1-INH deficiency), allergy, anaphylaxis, insect bite, trauma, infection, abscess,&#xD;
             tumor, post-radiation or post-operative or processes related to salivary glands and&#xD;
             others where it is unlikely that the ACEI is causing the angioedema&#xD;
&#xD;
          -  Participation in a clinical trial of another investigational medicinal product (IMP)&#xD;
             within 30 days&#xD;
&#xD;
          -  Patients with acute urticaria&#xD;
&#xD;
          -  Patients with a medical history of any angioedema before taking an ACEI&#xD;
&#xD;
          -  Patients with an acute rash or hives in the face or somewhere else&#xD;
&#xD;
          -  Unstable angina or acute myocardial infarction&#xD;
&#xD;
          -  Acute heart failure&#xD;
&#xD;
          -  Serious concomitant illnesses that the physician considers to be a contraindication&#xD;
             for participation in the trial&#xD;
&#xD;
          -  Pregnancy and/or breast-feeding&#xD;
&#xD;
          -  Mental condition rendering the patients, in the opinion of the investigator, unable to&#xD;
             understand the nature, scope and possible consequences of the study;&#xD;
&#xD;
          -  Unlikely to comply with the protocol, e.g., uncooperative attitude, inability to&#xD;
             return for the follow-up visit, or unlikely to complete the study for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murat Bas, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum rechts der Isar, Hals-Nasen-Ohrenklinik, Ismaninger Str. 22 81675 München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum rechts der Isar Hals-Nasen-Ohrenklinik der TUM</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>June 29, 2010</study_first_submitted>
  <study_first_submitted_qc>June 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2010</study_first_posted>
  <last_update_submitted>December 22, 2011</last_update_submitted>
  <last_update_submitted_qc>December 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2011</last_update_posted>
  <keyword>ACE inhibitor induced angioedema</keyword>
  <keyword>Bradykinin</keyword>
  <keyword>Non-itching edema</keyword>
  <keyword>Non-allergic angioedema</keyword>
  <keyword>Quincke edema</keyword>
  <keyword>Drug induced angioedema</keyword>
  <keyword>Bradykinin B2 receptor antagonist</keyword>
  <keyword>Icatibant</keyword>
  <keyword>HOE 140</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Icatibant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

